Abstract
Acquired Immune Deficiency Syndrome is one of the world's serious health problems. Immune-based therapy is a new approach in the treatment of HIV infected patients. IMODTM with the ability to correct immune deficiencies has been introduced for the management of HIV infection. In the phase IV trial study the main objectives were to assess the possible side effects, evaluate its effect on CD4+ T Lymphocyte count and patients’ and physicians’ satisfactions for 600 HIV infected patients in 13 centers during 2007. The observed adverse events in patients included: headache and vertigo (1.2%), nausea (1.2%), gastritis (1.2%), phlebitis (1%) and mild rash (1%); serious adverse events were not observed in any of IMODTM recipients. Therefore it was not needed to terminate the treatment in any of patient. The results of this study demonstrated that daily prescription of IMODTM significantly increases T Lymphocyte CD4+ and Total Lymphocyte Count in HIV-positive patients. In addition, nearly 90% of the patients and 70% physicians are satisfied by IMODTM treatment.
Keywords: Efficacy, IMODTM, post marketing surveillance, safety, satisfaction, side effect.
Infectious Disorders - Drug Targets
Title:Post Marketing Surveillance on Safety and Efficacy of IMOD in Iranian Patients with HIV/AIDS
Volume: 13 Issue: 1
Author(s): Minoo Mohraz, Abbas Sedaghat, SeyedAhmad SeyedAlinaghi, Hossein Asheri, Saeid Mohammaddoust, Farhad Gharibdoost, Hamid Reza Khorram Khorshid, Mohammad Farhadi, Seyed Hesamedin Madani and Koorosh Kamali
Affiliation:
Keywords: Efficacy, IMODTM, post marketing surveillance, safety, satisfaction, side effect.
Abstract: Acquired Immune Deficiency Syndrome is one of the world's serious health problems. Immune-based therapy is a new approach in the treatment of HIV infected patients. IMODTM with the ability to correct immune deficiencies has been introduced for the management of HIV infection. In the phase IV trial study the main objectives were to assess the possible side effects, evaluate its effect on CD4+ T Lymphocyte count and patients’ and physicians’ satisfactions for 600 HIV infected patients in 13 centers during 2007. The observed adverse events in patients included: headache and vertigo (1.2%), nausea (1.2%), gastritis (1.2%), phlebitis (1%) and mild rash (1%); serious adverse events were not observed in any of IMODTM recipients. Therefore it was not needed to terminate the treatment in any of patient. The results of this study demonstrated that daily prescription of IMODTM significantly increases T Lymphocyte CD4+ and Total Lymphocyte Count in HIV-positive patients. In addition, nearly 90% of the patients and 70% physicians are satisfied by IMODTM treatment.
Export Options
About this article
Cite this article as:
Mohraz Minoo, Sedaghat Abbas, SeyedAlinaghi SeyedAhmad, Asheri Hossein, Mohammaddoust Saeid, Gharibdoost Farhad, Khorshid Khorram Hamid Reza, Farhadi Mohammad, Madani Hesamedin Seyed and Kamali Koorosh, Post Marketing Surveillance on Safety and Efficacy of IMOD in Iranian Patients with HIV/AIDS, Infectious Disorders - Drug Targets 2013; 13 (1) . https://dx.doi.org/10.2174/18715265112129990031
DOI https://dx.doi.org/10.2174/18715265112129990031 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Infant Breast-Feeding and Suppression of Biomarkers of Future Cardiovascular Disease
Current Nutrition & Food Science The Role of Psychiatrist in Organ Transplantation: From Gate-keeper to Patient's Advocate
Current Psychiatry Reviews Inflammation in Coronary Artery Disease and Acute Myocardial Infarction - is the Stage Set for Novel Therapies?
Current Pharmaceutical Design Neuroprotective Therapies for Alzheimers Disease
Current Pharmaceutical Design Omega-3 and Renal Function in Older Adults
Current Pharmaceutical Design Functional Characteristic of Snake Venom Disintegrins: Potential Therapeutic Implication
Current Pharmaceutical Design Patenting the Gene-Hubs of Endoplasmic Reticulum Stress: The Systems Biology Approach
Recent Patents on Biotechnology Polymorphism Gln27Glu of β2 Adrenergic Receptors in Patients with Ischaemic Cardiomyopathy
Current Vascular Pharmacology Neopterin: From Forgotten Biomarker to Leading Actor in Cardiovascular Pathophysiology
Current Vascular Pharmacology Neuroinflamm-Aging and Neurodegenerative Diseases: An Overview
CNS & Neurological Disorders - Drug Targets Acylation Stimulating Protein and Triacylglycerol Synthesis: Potential Drug Targets?
Current Pharmaceutical Design Inflammaging in Skin and other Tissues - The Roles of Complement System and Macrophage
Inflammation & Allergy - Drug Targets (Discontinued) Pharmacotherapy of Schizophrenia: The Past, Present and Future
Current Drug Therapy Recent Developments in Drug Design of NO-donor Hybrid Compounds
Mini-Reviews in Medicinal Chemistry Vitamin D and Infectious Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Small Molecule Antagonists of the Chemokine Receptor CCR5
Current Topics in Medicinal Chemistry Varicella-Zoster Virus Infections During Pregnancy: Epidemiology, Clinical Symptoms, Diagnosis, Prevention and Therapy
Current Pediatric Reviews Alstrom Syndrome: Genetics and Clinical Overview
Current Genomics Helicase Domain Containing Proteins in Human Disorders
Current Genomics Adverse Effects of Tacrolimus in Renal Transplant Patients from Living Donors
Current Drug Safety